Synthetic lethality of PARP inhibition in cancers lackingBRCA1andBRCA2mutations
- 15 April 2011
- journal article
- Published by Informa UK Limited in Cell Cycle
- Vol. 10 (8), 1192-1199
- https://doi.org/10.4161/cc.10.8.15273
Abstract
Utilizing the concept of synthetic lethality has provided new opportunities for the development of targeted therapies, by allowing the targeting of loss of function genetic aberrations. In cancer cells with BRCA1 or BRCA2 loss of function, which harbor deficiency of DNA repair by homologous recombination, inhibition of PARP1 enzymatic activity leads to an accumulation of single strand breaks that are converted to double strand breaks but cannot be repaired by homologous recombination. Inhibition of PARP has therefore been advanced as a novel targeted therapy for cancers harboring BRCA1/2 mutations. Preclinical and preliminary clinical evidence, however, suggests a potentially broader scope for PARP inhibitors. Loss of function of various proteins involved in double strand break repair other than BRCA1/2 has been suggested to be synthetically lethal with PARP inhibition. Inactivation of these genes has been reported in a subset of human cancers and might therefore constitute predictive biomarkers for PARP inhibition. Here we discuss the evidence that the clinical use of PARP inhibition may be broader than targeting of cancers in BRCA1/2 germ-line mutation carriers.Keywords
This publication has 92 references indexed in Scilit:
- Requirement for NBS1 in the S phase checkpoint response to DNA methylation combined with PARP inhibitionDNA Repair, 2011
- Mutations in BRCA2 and PALB2 in male breast cancer cases from the United StatesBreast Cancer Research and Treatment, 2010
- Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2Nature Structural & Molecular Biology, 2010
- Aurora‐A expressing tumour cells are deficient for homology‐directed DNA double strand‐break repair and sensitive to PARP inhibitionEMBO Molecular Medicine, 2010
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Molecular Medicine, 2009
- PALB2 Links BRCA1 and BRCA2 in the DNA-Damage ResponseCurrent Biology, 2009
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Minding the gap: The underground functions of BRCA1 and BRCA2 at stalled replication forksDNA Repair, 2007
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTENCell, 1998